BRPI9908914B1 - composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel. - Google Patents

composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel.

Info

Publication number
BRPI9908914B1
BRPI9908914B1 BRPI9908914-9A BRPI9908914A BRPI9908914B1 BR PI9908914 B1 BRPI9908914 B1 BR PI9908914B1 BR PI9908914 A BRPI9908914 A BR PI9908914A BR PI9908914 B1 BRPI9908914 B1 BR PI9908914B1
Authority
BR
Brazil
Prior art keywords
iron
compound
therapeutic composition
dextran
prophylaxis
Prior art date
Application number
BRPI9908914-9A
Other languages
English (en)
Inventor
Hans Berg Andreasen
Lars Christensen
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9908914(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of BRPI9908914A publication Critical patent/BRPI9908914A/pt
Publication of BRPI9908914B1 publication Critical patent/BRPI9908914B1/pt
Publication of BRPI9908914B8 publication Critical patent/BRPI9908914B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BRPI9908914-9 1998-03-25 1999-03-24 composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel. BRPI9908914B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
PCT/DK1999/000160 WO1999048533A1 (en) 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Publications (3)

Publication Number Publication Date
BRPI9908914A BRPI9908914A (pt) 2000-11-21
BRPI9908914B1 true BRPI9908914B1 (pt) 2012-06-12
BRPI9908914B8 BRPI9908914B8 (pt) 2021-07-06

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9908914-9 BRPI9908914B8 (pt) 1998-03-25 1999-03-24 composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel.

Country Status (28)

Country Link
US (1) US6291440B1 (pt)
EP (1) EP1066056B2 (pt)
JP (1) JP4558198B2 (pt)
KR (1) KR100612071B1 (pt)
CN (1) CN1147322C (pt)
AR (1) AR015738A1 (pt)
AT (1) ATE220560T1 (pt)
AU (1) AU740432B2 (pt)
BR (1) BRPI9908914B8 (pt)
CA (1) CA2322633C (pt)
CZ (1) CZ300823B6 (pt)
DE (1) DE69902154T3 (pt)
DK (2) DK172860B1 (pt)
EA (1) EA003427B1 (pt)
ES (1) ES2180279T5 (pt)
HK (1) HK1033426A1 (pt)
HU (1) HU228483B1 (pt)
ID (1) ID26778A (pt)
NO (1) NO329591B1 (pt)
NZ (1) NZ505983A (pt)
PL (1) PL195582B1 (pt)
PT (1) PT1066056E (pt)
SI (1) SI1066056T2 (pt)
SK (1) SK284499B6 (pt)
TR (1) TR200002733T2 (pt)
UA (1) UA70939C2 (pt)
WO (1) WO1999048533A1 (pt)
ZA (1) ZA200004016B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
WO2000061191A2 (en) * 1999-04-09 2000-10-19 Advanced Magnetics, Inc. Heat stable coated colloidal iron oxides
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
DE60307249T2 (de) * 2002-04-09 2007-03-15 Pharmacosmos Holding A/S Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP1973549B1 (en) 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
BRPI0924653B8 (pt) 2009-03-25 2021-05-25 Pharmacosmos Holding As composto de ferro-oligossacarídeo, composição e uso de deste composto
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
PT3212182T (pt) * 2014-10-27 2019-07-29 Pharmacosmos Holding As Tratamento ou prevenção da anemia em mamíferos não humanos em período de gestação e ninhada
BR112020004357A2 (pt) * 2017-09-11 2020-09-08 Pharmacosmos Holding A/S compostos de complexo de ferro para uso terapêutico
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药(苏州)股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普(天津)生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
CN118019542A (zh) 2021-08-03 2024-05-10 法码科思莫斯控股有限公司 用于在治疗伴侣动物缺铁中皮下使用的铁络合化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
DK117730A (pt)
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Also Published As

Publication number Publication date
KR20010034641A (ko) 2001-04-25
NO329591B1 (no) 2010-11-15
ATE220560T1 (de) 2002-08-15
DK1066056T4 (da) 2009-04-14
CZ300823B6 (cs) 2009-08-19
EA200000981A1 (ru) 2001-02-26
CN1147322C (zh) 2004-04-28
HK1033426A1 (en) 2001-08-31
DK172860B1 (da) 1999-08-16
PL195582B1 (pl) 2007-10-31
CA2322633C (en) 2009-01-27
KR100612071B1 (ko) 2006-08-11
DE69902154T2 (de) 2003-03-06
US6291440B1 (en) 2001-09-18
EP1066056B2 (en) 2008-12-10
PT1066056E (pt) 2002-12-31
HU228483B1 (en) 2013-03-28
ID26778A (id) 2001-02-08
BRPI9908914A (pt) 2000-11-21
CN1293577A (zh) 2001-05-02
EP1066056B1 (en) 2002-07-17
CZ20003535A3 (cs) 2001-04-11
DK1066056T3 (da) 2002-10-14
ZA200004016B (en) 2001-07-25
BRPI9908914B8 (pt) 2021-07-06
JP2002507582A (ja) 2002-03-12
DE69902154D1 (de) 2002-08-22
SI1066056T2 (sl) 2009-04-30
PL343164A1 (en) 2001-07-30
SK14092000A3 (sk) 2001-04-09
AR015738A1 (es) 2001-05-16
EP1066056A1 (en) 2001-01-10
SI1066056T1 (en) 2002-12-31
EA003427B1 (ru) 2003-04-24
HUP0101189A3 (en) 2003-12-29
HUP0101189A2 (hu) 2001-08-28
WO1999048533A1 (en) 1999-09-30
JP4558198B2 (ja) 2010-10-06
AU2827399A (en) 1999-10-18
TR200002733T2 (tr) 2000-12-21
NO20004151L (no) 2000-08-18
AU740432B2 (en) 2001-11-01
ES2180279T3 (es) 2003-02-01
ES2180279T5 (es) 2009-05-05
DE69902154T3 (de) 2009-07-09
NO20004151D0 (no) 2000-08-18
CA2322633A1 (en) 1999-09-30
DK42099A (da) 1999-08-16
UA70939C2 (uk) 2004-11-15
SK284499B6 (sk) 2005-05-05
NZ505983A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
BRPI9908914B8 (pt) composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel.
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
BRPI0316438B8 (pt) uso de eritropoietina em doenças cardíacas
WO2000074662A3 (en) Arthritis treatment
BRPI0414544A (pt) 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
BRPI0512636A (pt) adsorvente de fosfato baseado em sulfato de ferro
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
MY126527A (en) Novel dihydropyrimidines
BRPI0507423A (pt) composição para uso na lavagem ou tratamento de tecidos e um processo para fabricação dessa composição
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
GB0225474D0 (en) Therapeutic agents
AU1414899A (en) Surfactant-based antimicrobial compositions and methods for using same
PT1459751E (pt) (s,s)-reboxetina para tratar as enxaquecas
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
BR9814923A (pt) Método para tratamento de doença de alzheimer
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
DK1107795T3 (da) Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis
PL368948A1 (en) Process and composition for treating wood
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
WO1999011256A8 (fr) L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
BR9900821A (pt) Processo para melhorar a aparência de uma composição de polimento de piso, composição de veìculo para polimento de pisos, e, uso de ìon cobre divalente.

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24.03.2019